Can immune checkpoint drugs fight cancers beyond their approved uses?

NCT ID NCT07754292

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase 2 trial investigates whether immune checkpoint inhibitors—medicines that help the immune system attack cancer—can be effective when used off-label for different types of malignancies. Adults with cancer whose doctor is considering such treatment may join. Participants receive one of several ICI regimens, possibly combined with other therapies, and researchers track tumor response, side effects, and how long the disease stays controlled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
immune checkpoint inhibitors (ICIs) used off-label, alone or with other treatments
What this could lead to
If effective, this could expand treatment options for people with cancers that have not responded to standard therapies, potentially slowing disease progression.
What could go wrong
This is an early-phase trial, and off-label use may not work for all cancer types. Immune checkpoint inhibitors can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Froedtert & the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.